Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study
Observational comparative effectiveness and safety studies are often subject to immortal person‐time, a period of follow‐up during which outcomes cannot occur because of the treatment definition. Common approaches, like excluding immortal time from the analysis or naïvely including immortal time in...
Saved in:
Published in | Statistics in medicine Vol. 35; no. 26; pp. 4824 - 4836 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
20.11.2016
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Observational comparative effectiveness and safety studies are often subject to immortal person‐time, a period of follow‐up during which outcomes cannot occur because of the treatment definition. Common approaches, like excluding immortal time from the analysis or naïvely including immortal time in the analysis, are known to result in biased estimates of treatment effect. Other approaches, such as the Mantel–Byar and landmark methods, have been proposed to handle immortal time. Little is known about the performance of the landmark method in different scenarios. We conducted extensive Monte Carlo simulations to assess the performance of the landmark method compared with other methods in settings that reflect realistic scenarios. We considered four landmark times for the landmark method. We found that the Mantel–Byar method provided unbiased estimates in all scenarios, whereas the exclusion and naïve methods resulted in substantial bias when the hazard of the event was constant or decreased over time. The landmark method performed well in correcting immortal person‐time bias in all scenarios when the treatment effect was small, and provided unbiased estimates when there was no treatment effect. The bias associated with the landmark method tended to be small when the treatment rate was higher in the early follow‐up period than it was later. These findings were confirmed in a case study of chronic obstructive pulmonary disease. Copyright © 2016 John Wiley & Sons, Ltd. |
---|---|
Bibliography: | Agency for Healthcare Research and Quality, US Department of Health and Human Services - No. HHSA290-2005-0016-I-TO8 istex:F1366C990264E6AB682A19B9AF9A3809C005DB9E Centers for Medicare and Medicaid Services, US Department of Health and Human Services - No. 500-2010-00001I-TO6; No. 500-2010-00001I TO2 ArticleID:SIM7019 ark:/67375/WNG-7ZX8QZ4K-W SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0277-6715 1097-0258 1097-0258 |
DOI: | 10.1002/sim.7019 |